151 related articles for article (PubMed ID: 37862969)
1. Potential of cucurbitacin as an anticancer drug.
Li Y; Li Y; Yao Y; Li H; Gao C; Sun C; Zhuang J
Biomed Pharmacother; 2023 Dec; 168():115707. PubMed ID: 37862969
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity.
Cai Y; Fang X; He C; Li P; Xiao F; Wang Y; Chen M
Am J Chin Med; 2015; 43(7):1331-50. PubMed ID: 26503558
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement.
Kumar A; Sharma B; Sharma U; Parashar G; Parashar NC; Rani I; Ramniwas S; Kaur S; Haque S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1867-1878. PubMed ID: 37010571
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms.
Silvestre GFG; de Lucena RP; da Silva Alves H
Curr Med Chem; 2022; 29(21):3774-3789. PubMed ID: 34994307
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin: ancient compound shedding new light on cancer treatment.
Lee DH; Iwanski GB; Thoennissen NH
ScientificWorldJournal; 2010 Mar; 10():413-8. PubMed ID: 20209387
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends.
Tuli HS; Rath P; Chauhan A; Ranjan A; Ramniwas S; Sak K; Aggarwal D; Kumar M; Dhama K; Lee EHC; Yap KC; Capinpin SM; Kumar AP
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671442
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.
Silva IT; Geller FC; Persich L; Dudek SE; Lang KL; Caro MS; Durán FJ; Schenkel EP; Ludwig S; Simões CM
Invest New Drugs; 2016 Apr; 34(2):139-48. PubMed ID: 26780083
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacins as Anticancer Agents: A Patent Review.
Hussain H; Green IR; Saleem M; Khattak KF; Irshad M; Ali M
Recent Pat Anticancer Drug Discov; 2019; 14(2):133-143. PubMed ID: 30451116
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin IIa: A review of phytochemistry and pharmacology.
Zeng Y; Wang J; Huang Q; Ren Y; Li T; Zhang X; Yao R; Sun J
Phytother Res; 2021 Aug; 35(8):4155-4170. PubMed ID: 33724593
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus.
Dakeng S; Duangmano S; Jiratchariyakul W; U-Pratya Y; Bögler O; Patmasiriwat P
J Cell Biochem; 2012 Jan; 113(1):49-60. PubMed ID: 21866566
[TBL] [Abstract][Full Text] [Related]
11. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer.
Chen X; Bao J; Guo J; Ding Q; Lu J; Huang M; Wang Y
Anticancer Drugs; 2012 Sep; 23(8):777-87. PubMed ID: 22561419
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds.
Ríos JL; Andújar I; Escandell JM; Giner RM; Recio MC
Curr Pharm Des; 2012; 18(12):1663-76. PubMed ID: 22443631
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms.
Varela C; Melim C; Neves BG; Sharifi-Rad J; Calina D; Mamurova A; Cabral C
J Transl Med; 2022 Dec; 20(1):630. PubMed ID: 36585670
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin mediated regulation of deregulated oncogenic signaling cascades and non-coding RNAs in different cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways.
Lin X; Farooqi AA
Semin Cancer Biol; 2021 Aug; 73():302-309. PubMed ID: 33152487
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Antiproliferative Effects of a New Cucurbitacin B Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549.
Marostica LL; Silva IT; Kratz JM; Persich L; Geller FC; Lang KL; Caro MS; Durán FJ; Schenkel EP; Simões CM
Chem Res Toxicol; 2015 Oct; 28(10):1949-60. PubMed ID: 26372186
[TBL] [Abstract][Full Text] [Related]
16. Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21.
Escandell JM; Kaler P; Recio MC; Sasazuki T; Shirasawa S; Augenlicht L; Ríos JL; Klampfer L
Biochem Pharmacol; 2008 Jul; 76(2):198-207. PubMed ID: 18561895
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics.
Dai S; Wang C; Zhao X; Ma C; Fu K; Liu Y; Peng C; Li Y
Pharmacol Res; 2023 Jan; 187():106587. PubMed ID: 36460279
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacins attenuate microglial activation and protect from neuroinflammatory injury through Nrf2/ARE activation and STAT/NF-κB inhibition.
Park SY; Kim YH; Park G
Neurosci Lett; 2015 Nov; 609():129-36. PubMed ID: 26472707
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in the Application of Cucurbitacins as Anticancer Agents.
Zieniuk B; Pawełkowicz M
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887406
[TBL] [Abstract][Full Text] [Related]
20. ANTITUMOR AND APOPTOTIC EFFECTS OF CUCURBITACIN A IN A-549 LUNG CARCINOMA CELLS IS MEDIATED VIA G2/M CELL CYCLE ARREST AND M-TOR/PI3K/AKT SIGNALLING PATHWAY.
Wang WD; Liu Y; Su Y; Xiong XZ; Shang D; Xu JJ; Liu HJ
Afr J Tradit Complement Altern Med; 2017; 14(2):75-82. PubMed ID: 28573224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
